PARP1 and neoplasm: Multiple studies have shown that under selective pressure from PARP or ATR/CHK1 inhibitors, tumour cells can upregulate enzymes in the serine/glycine–folate cycle and de novo purine/pyrimidine synthesis, thereby increasing dNTP and NADPH supply.108, 109